Detailed description page of ThPDB2
| This page displays user query in tabular form. |
Th1018 details |
| Primary information | |
|---|---|
| ID | 10129 |
| Therapeutic ID | Th1018 |
| Protein Name | Secretin |
| Sequence | >Th1018_Secretin HSDGTFTSELSRLREGARLQRLLQGLV |
| Molecular Weight | 3039.44 |
| Chemical Formula | C130H220N44O39 |
| Isoelectric Point | 9.45 |
| Hydrophobicity | -0.463 |
| Melting point | NA |
| Half-life | 0.75 hours |
| Description | This drug is the synthetic form of natural secretin. It is prepared using solid phase peptide synthesis. Secretin is a peptide hormone produced in the S cells of the duodenum. Its main effect is to regulate the pH of the small intestine contents through the control of gastric acid secretion and buffering with bicarbonate. It was the first hormone to be discovered. |
| Indication/Disease | For diagnosis of pancreatic exocrine dysfunction and gastrinoma |
| Pharmacodynamics | Secretin is a hormone produced in the S cells of the duodenum in response to low local pH. It stimulates the secretion of bicarbonate from bicarbonate producing organs(liver, pancreas, Brunner's glands) when the pH drops below a set value. This helps neutralize the gastric acid entering the duodenum from the stomach. It also inhibits acid secretion from the stomach by reducing gastrin release from the G cells of the stomach. |
| Mechanism of Action | Secretin binds to the secretin receptor found on the lining of S cells in the duodenum and G cells in the stomach. Binding leads to the secrection of bicarbonate or the reduction of the secretion of gastrin. Properly functioning organs (duodenum, pancreas and stomach) should be responsive to this hormone. |
| Toxicity | n acute toxicity studies with mice and rabbits, a dose of 20 μg/kg of synthetic human secretin was not lethal with no clinical symptoms of toxicity. |
| Metabolism | NA |
| Absorption | Following intravenous bolus administration of 0.4 mcg/kg, synthetic human secretin concentration rapidly declines to baseline secretin levels within 90 to 120 minutes |
| 2.7 L | |
| Clearance | 580.9 ± 51.3 mL/min |
| Categories | Amino Acids, Peptides, and Proteins, Diagnostic Agents, Gastrointestinal Agents, Gastrointestinal Hormones, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Nerve Tissue Proteins, Neuropeptides, Peptide Hormones, Peptides, Proteins, Secretin, Secretin-class Hormone, Tests for Pancreatic Function |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | Clidinium. Anticholinergic agents such as secretin may diminish the stimulatory effect of secretin. Avoid using drugs with substantial anticholinergic effects in patients receiving secretin whenever possible. If such agents must be used in combina |
| Target | Secretin receptor |
| Brand Name | SecreFlo |
| Company | Repligen Corp |
| Brand Description | Repligen Corp |
| Prescribed For | Testing for stimulation of pancreatic secretions, including bicarbonate, to aid in the diagnosis of pancreatic exocrine dysfunction. |
| Chemical Name | H-His-Ser-Asp-Gly-Thr-Phe-Thr-Ser-Glu-Leu-Ser-Arg-Leu-Arg-Asp-Ser- Ala-Arg-Leu-Gln-Arg-Leu-Leu-Gln-Gly-Leu-Val-NH2 |
| Formulation | NA |
| Physical Appearance | Lyophilized white powder |
| Route of Administration | Intravenous infusion |
| Recommended Dosage | NA |
| Contraindication | Allergy |
| Side Effects | Abdominal discomfort, Nausea, Mild bradycardia (reduced heart rate), Decreased blood pressure and Diaphoresis (profuse perspiration) |
| Useful Link 1 | Link |
| Useful Link 2 | NA |
| Remarks | NA |
| Primary information | |
|---|---|
| ID | 10130 |
| Therapeutic ID | Th1018 |
| Protein Name | Secretin |
| Sequence | >Th1018_Secretin HSDGTFTSELSRLREGARLQRLLQGLV |
| Molecular Weight | 3039.44 |
| Chemical Formula | C130H220N44O40 |
| Isoelectric Point | 9.45 |
| Hydrophobicity | -0.463 |
| Melting point | NA |
| Half-life | 0.75 hours |
| Description | This drug is the synthetic form of natural secretin. It is prepared using solid phase peptide synthesis. Secretin is a peptide hormone produced in the S cells of the duodenum. Its main effect is to regulate the pH of the small intestine contents through the control of gastric acid secretion and buffering with bicarbonate. It was the first hormone to be discovered. |
| Indication/Disease | For diagnosis of pancreatic exocrine dysfunction and gastrinoma |
| Pharmacodynamics | Secretin is a hormone produced in the S cells of the duodenum in response to low local pH. It stimulates the secretion of bicarbonate from bicarbonate producing organs(liver, pancreas, Brunner's glands) when the pH drops below a set value. This helps neutralize the gastric acid entering the duodenum from the stomach. It also inhibits acid secretion from the stomach by reducing gastrin release from the G cells of the stomach. |
| Mechanism of Action | Secretin binds to the secretin receptor found on the lining of S cells in the duodenum and G cells in the stomach. Binding leads to the secrection of bicarbonate or the reduction of the secretion of gastrin. Properly functioning organs (duodenum, pancreas and stomach) should be responsive to this hormone. |
| Toxicity | n acute toxicity studies with mice and rabbits, a dose of 20 μg/kg of synthetic human secretin was not lethal with no clinical symptoms of toxicity. |
| Metabolism | NA |
| Absorption | Following intravenous bolus administration of 0.4 mcg/kg, synthetic human secretin concentration rapidly declines to baseline secretin levels within 90 to 120 minutes |
| 2.7 L | |
| Clearance | 580.9 ± 51.3 mL/min |
| Categories | Amino Acids, Peptides, and Proteins, Diagnostic Agents, Gastrointestinal Agents, Gastrointestinal Hormones, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Nerve Tissue Proteins, Neuropeptides, Peptide Hormones, Peptides, Proteins, Secretin, Secretin-class Hormone, Tests for Pancreatic Function |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | Tiotropium.The stimulatory effect of Secretin may be reduced by anticholinergics such as Tiotropium. Concomitant use of Secretin and drugs with substantial anticholinergic effects should be avoided. |
| Target | NA |
| Brand Name | ChiRhoStim |
| Company | ChiRhoClin, Inc |
| Brand Description | ChiRhoClin, Inc |
| Prescribed For | Testing for stimulation of gastrin secretion to aid in the diagnosis of gastrinoma. |
| Chemical Name | NA |
| Formulation | As a 10 mL single-dose vial which contains 16 mcg of purified synthetic human secretin, 1.5 mg of Lcysteine hydrochloride, 20 mg of mannitol, and 9 mg of sodium chloride. When reconstituted in 8 mL of Sodium Chloride Injection USP, each mL of solution contains 2 mcg synthetic human secretin for intravenous use. The pH of the reconstituted solution has a range of 3 to 6.5. |
| Physical Appearance | white lyophilized sterile powder |
| Route of Administration | Intravenous infusion |
| Recommended Dosage | 0.2 mcg/kg by intravenous injection over 1 minute |
| Contraindication | NA |
| Side Effects | Nausea Vomiting Flushing Upset stomach |
| Useful Link 1 | Link |
| Useful Link 2 | NA |
| Remarks | NA |
| Primary information | |
|---|---|
| ID | 10131 |
| Therapeutic ID | Th1018 |
| Protein Name | Secretin |
| Sequence | >Th1018_Secretin HSDGTFTSELSRLREGARLQRLLQGLV |
| Molecular Weight | 3039.44 |
| Chemical Formula | C130H220N44O41 |
| Isoelectric Point | 9.45 |
| Hydrophobicity | -0.463 |
| Melting point | NA |
| Half-life | 0.75 hours |
| Description | This drug is the synthetic form of natural secretin. It is prepared using solid phase peptide synthesis. Secretin is a peptide hormone produced in the S cells of the duodenum. Its main effect is to regulate the pH of the small intestine contents through the control of gastric acid secretion and buffering with bicarbonate. It was the first hormone to be discovered. |
| Indication/Disease | For diagnosis of pancreatic exocrine dysfunction and gastrinoma |
| Pharmacodynamics | Secretin is a hormone produced in the S cells of the duodenum in response to low local pH. It stimulates the secretion of bicarbonate from bicarbonate producing organs(liver, pancreas, Brunner's glands) when the pH drops below a set value. This helps neutralize the gastric acid entering the duodenum from the stomach. It also inhibits acid secretion from the stomach by reducing gastrin release from the G cells of the stomach. |
| Mechanism of Action | Secretin binds to the secretin receptor found on the lining of S cells in the duodenum and G cells in the stomach. Binding leads to the secrection of bicarbonate or the reduction of the secretion of gastrin. Properly functioning organs (duodenum, pancreas and stomach) should be responsive to this hormone. |
| Toxicity | n acute toxicity studies with mice and rabbits, a dose of 20 μg/kg of synthetic human secretin was not lethal with no clinical symptoms of toxicity. |
| Metabolism | NA |
| Absorption | Following intravenous bolus administration of 0.4 mcg/kg, synthetic human secretin concentration rapidly declines to baseline secretin levels within 90 to 120 minutes |
| 2.7 L | |
| Clearance | 580.9 ± 51.3 mL/min |
| Categories | Amino Acids, Peptides, and Proteins, Diagnostic Agents, Gastrointestinal Agents, Gastrointestinal Hormones, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Nerve Tissue Proteins, Neuropeptides, Peptide Hormones, Peptides, Proteins, Secretin, Secretin-class Hormone, Tests for Pancreatic Function |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | Tolterodine.The stimulatory effect of Secretin may be reduced by anticholinergics such as Tolterodine. Concomitant use of Secretin and drugs with substantial anticholinergic effects should be avoided. If combination therapy must be used, Secretin |
| Target | NA |
| Brand Name | Secretin Inj 75unit/vial |
| Company | Ferring Pharmaceuticals |
| Brand Description | Ferring Pharmaceuticals |
| Prescribed For | Testing for stimulation of pancreatic secretions to facilitate the identification of the ampulla of Vater and accessory papilla during endoscopic retrograde cholangiopancreatography(ERCP). |
| Chemical Name | NA |
| Formulation | NA |
| Physical Appearance | NA |
| Route of Administration | NA |
| Recommended Dosage | NA |
| Contraindication | NA |
| Side Effects | NA |
| Useful Link 1 | NA |
| Useful Link 2 | NA |
| Remarks | NA |
| Primary information | |
|---|---|
| ID | 10132 |
| Therapeutic ID | Th1018 |
| Protein Name | Secretin |
| Sequence | >Th1018_Secretin HSDGTFTSELSRLREGARLQRLLQGLV |
| Molecular Weight | 3039.44 |
| Chemical Formula | C130H220N44O42 |
| Isoelectric Point | 9.45 |
| Hydrophobicity | -0.463 |
| Melting point | NA |
| Half-life | 0.75 hours |
| Description | This drug is the synthetic form of natural secretin. It is prepared using solid phase peptide synthesis. Secretin is a peptide hormone produced in the S cells of the duodenum. Its main effect is to regulate the pH of the small intestine contents through the control of gastric acid secretion and buffering with bicarbonate. It was the first hormone to be discovered. |
| Indication/Disease | For diagnosis of pancreatic exocrine dysfunction and gastrinoma |
| Pharmacodynamics | Secretin is a hormone produced in the S cells of the duodenum in response to low local pH. It stimulates the secretion of bicarbonate from bicarbonate producing organs(liver, pancreas, Brunner's glands) when the pH drops below a set value. This helps neutralize the gastric acid entering the duodenum from the stomach. It also inhibits acid secretion from the stomach by reducing gastrin release from the G cells of the stomach. |
| Mechanism of Action | Secretin binds to the secretin receptor found on the lining of S cells in the duodenum and G cells in the stomach. Binding leads to the secrection of bicarbonate or the reduction of the secretion of gastrin. Properly functioning organs (duodenum, pancreas and stomach) should be responsive to this hormone. |
| Toxicity | n acute toxicity studies with mice and rabbits, a dose of 20 μg/kg of synthetic human secretin was not lethal with no clinical symptoms of toxicity. |
| Metabolism | NA |
| Absorption | Following intravenous bolus administration of 0.4 mcg/kg, synthetic human secretin concentration rapidly declines to baseline secretin levels within 90 to 120 minutes |
| 2.7 L | |
| Clearance | 580.9 ± 51.3 mL/min |
| Categories | Amino Acids, Peptides, and Proteins, Diagnostic Agents, Gastrointestinal Agents, Gastrointestinal Hormones, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Nerve Tissue Proteins, Neuropeptides, Peptide Hormones, Peptides, Proteins, Secretin, Secretin-class Hormone, Tests for Pancreatic Function |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | Trihexyphenidyl.The stimulatory effect of Secretin may be reduced by anticholinergics such as Trihexyphenidyl. Concomitant use of Secretin and drugs with substantial anticholinergic effects should be avoided. If combination therapy must be used, S |
| Target | NA |
| Brand Name | Secremax |
| Company | Repligen Corp |
| Brand Description | Repligen Corp |
| Prescribed For | Used to treat GI spasm, irritable bowel syndrome, hyperperistalsis, peptic ulcer, functional diarrhoea, morning sickness, motion sickness and Dismenorrhoea. |
| Chemical Name | NA |
| Formulation | NA |
| Physical Appearance | Solution |
| Route of Administration | Intravenous |
| Recommended Dosage | NA |
| Contraindication | NA |
| Side Effects | NA |
| Useful Link 1 | Link |
| Useful Link 2 | NA |
| Remarks | NA |
| Primary information | |
|---|---|
| ID | 10133 |
| Therapeutic ID | Th1018 |
| Protein Name | Secretin |
| Sequence | >Th1018_Secretin HSDGTFTSELSRLREGARLQRLLQGLV |
| Molecular Weight | 3039.44 |
| Chemical Formula | C130H220N44O43 |
| Isoelectric Point | 9.45 |
| Hydrophobicity | -0.463 |
| Melting point | NA |
| Half-life | 0.75 hours |
| Description | This drug is the synthetic form of natural secretin. It is prepared using solid phase peptide synthesis. Secretin is a peptide hormone produced in the S cells of the duodenum. Its main effect is to regulate the pH of the small intestine contents through the control of gastric acid secretion and buffering with bicarbonate. It was the first hormone to be discovered. |
| Indication/Disease | For diagnosis of pancreatic exocrine dysfunction and gastrinoma |
| Pharmacodynamics | Secretin is a hormone produced in the S cells of the duodenum in response to low local pH. It stimulates the secretion of bicarbonate from bicarbonate producing organs(liver, pancreas, Brunner's glands) when the pH drops below a set value. This helps neutralize the gastric acid entering the duodenum from the stomach. It also inhibits acid secretion from the stomach by reducing gastrin release from the G cells of the stomach. |
| Mechanism of Action | Secretin binds to the secretin receptor found on the lining of S cells in the duodenum and G cells in the stomach. Binding leads to the secrection of bicarbonate or the reduction of the secretion of gastrin. Properly functioning organs (duodenum, pancreas and stomach) should be responsive to this hormone. |
| Toxicity | n acute toxicity studies with mice and rabbits, a dose of 20 μg/kg of synthetic human secretin was not lethal with no clinical symptoms of toxicity. |
| Metabolism | NA |
| Absorption | Following intravenous bolus administration of 0.4 mcg/kg, synthetic human secretin concentration rapidly declines to baseline secretin levels within 90 to 120 minutes |
| 2.7 L | |
| Clearance | 580.9 ± 51.3 mL/min |
| Categories | Amino Acids, Peptides, and Proteins, Diagnostic Agents, Gastrointestinal Agents, Gastrointestinal Hormones, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Nerve Tissue Proteins, Neuropeptides, Peptide Hormones, Peptides, Proteins, Secretin, Secretin-class Hormone, Tests for Pancreatic Function |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | Trimethobenzamide.The stimulatory effect of Secretin may be reduced by anticholinergics such as Trimethobenzamide. Concomitant use of Secretin and drugs with substantial anticholinergic effects should be avoided. If combination therapy must be use |
| Target | NA |
| Brand Name | NA |
| Company | NA |
| Brand Description | NA |
| Prescribed For | NA |
| Chemical Name | NA |
| Formulation | NA |
| Physical Appearance | NA |
| Route of Administration | NA |
| Recommended Dosage | NA |
| Contraindication | NA |
| Side Effects | NA |
| Useful Link 1 | Link |
| Useful Link 2 | NA |
| Remarks | NA |
| Primary information | |
|---|---|
| ID | 10134 |
| Therapeutic ID | Th1018 |
| Protein Name | Secretin |
| Sequence | >Th1018_Secretin HSDGTFTSELSRLREGARLQRLLQGLV |
| Molecular Weight | 3039.44 |
| Chemical Formula | C130H220N44O44 |
| Isoelectric Point | 9.45 |
| Hydrophobicity | -0.463 |
| Melting point | NA |
| Half-life | 0.75 hours |
| Description | This drug is the synthetic form of natural secretin. It is prepared using solid phase peptide synthesis. Secretin is a peptide hormone produced in the S cells of the duodenum. Its main effect is to regulate the pH of the small intestine contents through the control of gastric acid secretion and buffering with bicarbonate. It was the first hormone to be discovered. |
| Indication/Disease | For diagnosis of pancreatic exocrine dysfunction and gastrinoma |
| Pharmacodynamics | Secretin is a hormone produced in the S cells of the duodenum in response to low local pH. It stimulates the secretion of bicarbonate from bicarbonate producing organs(liver, pancreas, Brunner's glands) when the pH drops below a set value. This helps neutralize the gastric acid entering the duodenum from the stomach. It also inhibits acid secretion from the stomach by reducing gastrin release from the G cells of the stomach. |
| Mechanism of Action | Secretin binds to the secretin receptor found on the lining of S cells in the duodenum and G cells in the stomach. Binding leads to the secrection of bicarbonate or the reduction of the secretion of gastrin. Properly functioning organs (duodenum, pancreas and stomach) should be responsive to this hormone. |
| Toxicity | n acute toxicity studies with mice and rabbits, a dose of 20 μg/kg of synthetic human secretin was not lethal with no clinical symptoms of toxicity. |
| Metabolism | NA |
| Absorption | Following intravenous bolus administration of 0.4 mcg/kg, synthetic human secretin concentration rapidly declines to baseline secretin levels within 90 to 120 minutes |
| 2.7 L | |
| Clearance | 580.9 ± 51.3 mL/min |
| Categories | Amino Acids, Peptides, and Proteins, Diagnostic Agents, Gastrointestinal Agents, Gastrointestinal Hormones, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Nerve Tissue Proteins, Neuropeptides, Peptide Hormones, Peptides, Proteins, Secretin, Secretin-class Hormone, Tests for Pancreatic Function |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | Trospium.The stimulatory effect of Secretin may be reduced by anticholinergics such as Trospium. Concomitant use of Secretin and drugs with substantial anticholinergic effects should be avoided. If combination therapy must be used, Secretin effica |
| Target | NA |
| Brand Name | NA |
| Company | NA |
| Brand Description | NA |
| Prescribed For | NA |
| Chemical Name | NA |
| Formulation | NA |
| Physical Appearance | NA |
| Route of Administration | NA |
| Recommended Dosage | NA |
| Contraindication | NA |
| Side Effects | NA |
| Useful Link 1 | NA |
| Useful Link 2 | NA |
| Remarks | NA |